- Home
- CPRX vs HAE Comparison
CPRX vs HAE Comparison
Compare CPRX & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- HAE
- Stock Information
- Founded
- CPRX 2002
- HAE 1971
- Country
- CPRX United States
- HAE United States
- Employees
- CPRX N/A
- HAE N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- HAE Medical/Dental Instruments
- Sector
- CPRX Health Care
- HAE Health Care
- Exchange
- CPRX Nasdaq
- HAE Nasdaq
- Market Cap
- CPRX 2.6B
- HAE 2.5B
- IPO Year
- CPRX 2006
- HAE 1991
- Fundamental
- Price
- CPRX $21.29
- HAE $51.38
- Analyst Decision
- CPRX Strong Buy
- HAE Buy
- Analyst Count
- CPRX 5
- HAE 8
- Target Price
- CPRX $33.20
- HAE $76.88
- AVG Volume (30 Days)
- CPRX 1.4M
- HAE 695.5K
- Earning Date
- CPRX 11-05-2025
- HAE 11-06-2025
- Dividend Yield
- CPRX N/A
- HAE N/A
- EPS Growth
- CPRX 183.96
- HAE 46.89
- EPS
- CPRX 1.65
- HAE 3.28
- Revenue
- CPRX $558,499,000.00
- HAE $1,346,046,000.00
- Revenue This Year
- CPRX $16.59
- HAE N/A
- Revenue Next Year
- CPRX $8.80
- HAE $6.42
- P/E Ratio
- CPRX $12.72
- HAE $15.64
- Revenue Growth
- CPRX 28.55
- HAE 0.91
- 52 Week Low
- CPRX $19.05
- HAE $47.32
- 52 Week High
- CPRX $26.58
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- CPRX 57.67
- HAE 51.68
- Support Level
- CPRX $20.66
- HAE $50.30
- Resistance Level
- CPRX $21.55
- HAE $51.89
- Average True Range (ATR)
- CPRX 0.57
- HAE 1.41
- MACD
- CPRX 0.05
- HAE 0.54
- Stochastic Oscillator
- CPRX 84.24
- HAE 81.89
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.